Viking Therapeutics, Inc.
VKTX
$24.99
-$0.67-2.61%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -66.80% | -43.94% | -10.68% | -15.73% | -40.06% |
| Total Depreciation and Amortization | 50.00% | 48.65% | 19.18% | 2.74% | 2.78% |
| Total Amortization of Deferred Charges | -14.29% | -7.69% | 1,100.00% | -43.75% | 0.00% |
| Total Other Non-Cash Items | 59.12% | 18.59% | 189.67% | -37.82% | 61.94% |
| Change in Net Operating Assets | -194.43% | -55.16% | -170.93% | -259.62% | 289.80% |
| Cash from Operations | -753.13% | -76.76% | -11.72% | -149.35% | 75.11% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 113.76% | -81.57% | 306.65% | 38.35% | -21,018.65% |
| Cash from Investing | 113.76% | -81.57% | 306.65% | 38.35% | -21,018.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.95% | 431.91% | -- | -98.93% | 10,820.61% |
| Repurchase of Common Stock | -- | -- | 100.00% | 100.00% | -2,356.30% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.94% | 431.91% | 3,508.11% | -98.91% | 14,384.63% |
| Foreign Exchange rate Adjustments | 102.08% | -248.00% | 57.35% | 200.00% | -433.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -91.96% | -229.13% | 119.89% | -396.47% | 866.63% |